Stockwatch: The Mixed History Of Biotech Company Separations
Was Bluebird’s Split Accompanied By Premature Enthusiasm?
The path of spin-offs from loss-making biotech companies with weak investment propositions seems clouded with examples that often resulted in an appointment with the liquidator.
You may also be interested in...
The company is deferring investment in a US commercial team and prioritizing R&D activities, but it outlined an accelerated path to approval for LentiGlobin in sickle cell disease.
Depending on the therapeutic area, a fall in pharmaceutical sales was an obvious effect of the pandemic, although lower selling and marketing expenses and fewer non-COVID-19 infections were minor positives.
Roche’s full-year 2020 results suggested that it had seen better days. By contrast, the turnaround narrative at AstraZeneca suggested that its worst days were behind it.